Animal Flunixin Meglumine Injection 5%
|Terms of Trade:||FOB,CFR,CIF|
|Min. Order:||5000 Bag/Bags|
|Delivery Time:||25 Days|
|Packaging:||5% 100ml/bottle/box, 80bottles/carton|
|Productivity:||20000 bottles per day|
|Place of Origin:||Hebei, China (Mainland)|
|Supply Ability:||20000 bottles per day|
Model No.: 5% 100ml
Flunixin meglumine Injection 5%
Flunixin meglumine Injection 5% is a relatively potent non-narcotic, non-steroidal analgesic with anti-inflammatory and anti-pyretic properties. In the horse, Flunixin Injection is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders especially in acute and chronic stages and for the alleviation of visceral pain associated with colic. In cattle,Flunixin Meglumine Injection is indicated for the control of acute inflammation associated with respiratory disease.Flunixin Injection can not administer to pregnant animals.
Dosage Administration:Flunixin Injection is indicated for intravenous administration to cattle and horses. HORSES: For use in equine colic, the recommended dose rate is 1.1 mg flunixin/kg bodyweight equivalent to 1 ml per 45 kg bodyweight by intravenous injection. Treatment may be repeated once or twice if colic recurs. For use in musculo-skeletal disorders, the recommended dose rate is 1.1 mg flunixin/kg bodyweight, equivalent to 1 ml per 45 kg bodyweight injected intravenously once daily for up to 5 days according to clinical response. CATTLE: The recommended dose rate is 2.2 mg flunixin/kg bodyweight equivalent to 2 ml per 45 kg bodyweight injected intravenously and repeated as necessary at 24 hour intervals for up to 3 consecutive days.
Do not administer to pregnant animals. Monitor drug compatibility closely where adjunctive therapy is required. Avoid intra-arterial injection. It is preferable that NSAIDs, which inhibit prostaglandin synthesis, are not administered to animals undergoing general anaesthesia until fully recovered. Horses intended for racing and competition should be treated according to local requirements and appropriate precautions must be taken to ensure compliance with the competition regulations. In case of doubt it is advisable to test the urine. The cause of the underlying inflammatory condition or colic should be determined and treated with appropriate concomitant therapy.Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product. Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects. Use in any animal less than 6 weeks of age or in aged animals may involve an additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided. In case of spillage onto skin wash immediately with water. To avoid possible sensitisation reactions, avoid contact with the skin. Gloves should be worn during application. The product may cause reactions in sensitive individuals. If you have known hypersensitivity for non-steriodal anti-inflammatory products do not handle the product. Reactions may be serious.
Cattle may be slaughtered for human consumption only after 14 days from the last treatment. Horses may be slaughtered for human consumption only after 28 days from the last treatment. Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from treated cows after 2 days from the last treatment.
Do not store above 25℃. Protect from light. Store out of reach of children. Avoid introduction of contamination. Following withdrawal of the first dose, use the product within 28 days. Discard unused product. At the first time of use, insert the date to discard the product on the label.
Hebei Kexing Pharmaceutical Co., Ltd.
Hebei Kexing Pharmaceutical Co., Ltd., founded in 1996, is a high-tech private enterprise integrating the R&D, manufacture and marketing of animal healthy products. Our company has gained reliance and support from numerous customers by high-quality starting, serious and scientific management, excellent product quality and brand-new aftermarket service.
Our company has internationally first-class production processing plants. We invest RMB60 million in building the GMP main plant composed of four floors, with a total area of 7455 square meters. Our plant is one of the biggest animal drug preparation plants in China. Among them, there are six production lines respectively for Water Injection, large infusion, oral liquid, powder, Tablets and disinfectants; three lines for powder.
Annual output as follows: injection reaches 15 million tons; large infusion reaches 150,000 bottles, tablets reach 150 million pieces, powder achieves 600 tons and canned products achieve 1200 tons.
Total production value reaches more than 125 millions. Our eight dynamic production lines have passed through GMP certification of National Ministry of Agriculture at one time since September 2004. Project phase 2, including one TCM extraction line and one powder production line, comprehensive office buildings and animal houses for tests, will promote the R&D and manufacture ability of our company forward, and establish solid foundation of developing export trade.
Kexing will maintain safe production and share wonderful tomorrow with every client!
- Company Name: Hebei Kexing Pharmaceutical Co., Ltd.
- Representative: yangguangping
- Product/Service: Veterinary Injection , Veterinary Solution , Veterinary Powder , Veterinary Tablet , Veterinary Disinfectant , Veterinary Premix
- Capital (Million US $): 50,000,000RMB
- Year Established: 1996
- Total Annual Sales Volume (Million US $): US$50 Million - US$100 Million
- Export Percentage: 31% - 40%
- Total Annual Purchase Volume (Million US $): US$10 Million - US$50 Million
- No. of Production Lines: 14
- No. of R&D Staff: 31 -40 People
- No. of QC Staff: 41 -50 People
- OEM Services Provided: yes
- Factory Size (Sq.meters): 30,000-50,000 square meters
- Factory Location: 114 Changsheng Street, Luquan Development Zone, Shijiazhuang City,Hebei
- Contact Person: Mr. kenneth Yang
- Tel: 86-311-80677112
Premium Related Products